Abiopharma

🔍 BERKOWITZ BRUCE R (Executive)

Company: ST JOE Co (JOE)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Sold 189,200 shares of Common Stock at $65.78 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,884,424.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 163,600 shares of Common Stock at $65.78 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,720,824.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 25,000 shares of Common Stock at $65.33 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,695,824.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: H | shares_owned_after: 606,866.00 | Footnotes: F2

Footnotes:

• F1: The reported transactions were in securities held by The Fairholme Fund, a series of Fairholme Funds, Inc. (the "Fairholme Fund"). The securities may be deemed to be beneficially owned by Mr. Bruce R. Berkowitz ("Mr. Berkowitz") because he controls the sole member of Fairholme Capital Management, LLC ("Fairholme"), which may be deemed to have beneficial ownership of the securities because Fairholme serves as the investment manager to the Fairholme Fund. Mr. Berkowitz and Fairholme disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Berkowitz and Fairholme are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
• F2: The reported securities are directly owned by Mr. Berkowitz.